Condition: Refractory Ventricular Tachycardia · Sponsor: Thermedical, Inc.
The Thermedical Ablation System and Durablate catheter is indicated for use in patients with recurrent, sustained, monomorphic ventricular tachycardia (SMVT) refractory to drug therapy and conventional (approved) catheter ablation. Subjects with recurrent, SMVT refractory to drug therapy and conventional catheter ablation who are not eligible for, or will not likely benefit from repeat endocardial ablation using an approved catheter.
This description comes directly from the study's public registry record.
Michael Curley, PhD · 617-899-9843 · mcurley@thermedical.com
Mary DeVoe · m.devoe@thermedical.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Not Yet Recruiting |
| Hospital of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Not Yet Recruiting |
| Medical University of South Carolina | Charleston, South Carolina, United States | Not Yet Recruiting |
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | Not Yet Recruiting |
| Intermountain Healthcare | Salt Lake City, Utah, United States | Recruiting |
| Montreal Heart Institute - Institut de Cardiologie de Montréal | Montreal, Quebec, Canada | Recruiting |
| Quebec Heart and Lung Institute - Institut universitaire de cardiologie et de pneumologie de Québec | Québec, Quebec, Canada | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05337241